IgG – Page 43 – Communicable Diseases Research

Endothelial Cell-Activating Antibodies in COVID-19

COVID-19의 내피 세포 활성화 항체

Article

Published on 2022-07-012022-09-12
Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] MERS, 진단,

Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah

Article

Published on 2022-07-012022-11-15
Journal: Annals of Saudi medicine [Category] COVID19(2023년), SARS, 진단,

A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity

SARS-CoV-2 델타 변이형 돌발성 감염 및 가정전파 증례: 백신의 역할, 스파이크 방지 IgG 및 중화 활성

Case Reports

Published on 2022-07-012022-09-11
Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG Antibody titers BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections Case report Clinical course clinical symptom contribute coronavirus defined Delta delta variant dose female Fever gradually increased healthcare worker IgG Immunoglobulin Immunoglobulin G index case individual individuals Infection Neutralizing activity Neutralizing antibodies neutralizing antibody occur patients remained respiratory role SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralizing antibody secondary case severe acute respiratory syndrome Coronavirus the SARS-CoV-2 vaccinated individual vaccinated individuals vaccination Vaccine variant
[DOI] 10.1016/j.jiac.2022.02.003 PMC 바로가기 [Article Type] Case Reports

Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome

원발성 항인지질 증후군 환자에서 SARS-CoV-2 백신 후 면역원성, 안전성 및 항인지질항체

Article

Published on 2022-07-012022-09-12
Journal: Lupus [Category] COVID19(2023년), MERS, SARS, 진단,

Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2

중증급성호흡기증후군 코로나바이러스 2에 대한 현장 진료 대리 중화 시험을 이용한 백신 유발 효과의 이질성 평가

Article

Published on 2022-07-012022-09-12
Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), MERS, SARS, 진단,

SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

항체 결핍증이 있는 개인의 SARS-CoV-2 백신 반응: COV-AD 연구 결과

Article

Published on 2022-07-012022-09-12
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] Antibiotic prophylaxis antibody Antibody Response assays AstraZeneca Breakthrough infection cellular response clearance Cohort controls COVID-19 CVID deficiency determine dose Efficacy ELISA Evidence finding General population healthy control IgG immune response immunoglobulin replacement therapy Inborn error inborn errors of immunity individual Infection interferon gamma less magnitude morbidity and mortality nasopharyngeal swabs neutralisation neutralising no difference occurred participant Patient PCR PCR positive Pfizer/BioNTech post vaccination Prevent Primary Immunodeficiency receiving recipient recruited recurrent infection reduced remained reported respond response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary secondary antibody secondary immunodeficiency seropositive Seropositivity significantly T cell response the antibody response vaccination Vaccine Vaccines
[DOI] 10.1007/s10875-022-01231-7 PMC 바로가기 [Article Type] Article

IgG N-glycome changes during the course of severe COVID-19: An observational study

중증 코로나19 기간 동안 IgG N-글리코메 변화: 관찰 연구

Meta-Analysis

Published on 2022-07-012022-09-12
Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단,

[키워드] 95% CI acute respiratory syndrome adjusted Affect age analysed Analysis bind Bisecting GlcNAc cause change changes in circulating Cohort cohorts competence complement system activation contrary coronavirus disease Coronavirus-2 Course COVID-19 COVID-19 case cytotoxicity determine education European Fc region foundation functions Fund Galactosylation glycan glycans glycosylation Health IgG IgG glycosylation immune cells immune response Immunoglobulin immunoglobulins immunosuppressive independent indicate Investment IQR lack magnitude males median age Meta-analysis Mild mild case Molecular epidemiology molecular mechanism Multiple Patient performed problem proinflammatory receptor regulate released Respiratory illness SARS-CoV-2 Science Severe case severe COVID-19 severe COVID-19 patient severity significantly statistically statistically significant supported the disease Youth
[DOI] 10.1016/j.ebiom.2022.104101 PMC 바로가기 [Article Type] Meta-Analysis

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

신장 이식 수혜자에서 세 번째 mRNA SARS-CoV-2 백신 접종 후 B.1.617.2(델타) 및 B.1.1.529(오미크론) 변이체에 대한 중화 항체 반응

Observational Study

Published on 2022-07-012022-09-11
Journal: American journal of transplantation : official jou [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] addition Anti-RBD antibodies anti-receptor-binding domain antibody antibody response against B.1.1.529 B.1.617.2 clinical decision-making Clinical research COVID-19 vaccination cross-neutralization detectable dose healthy control healthy controls IgG immune immune modulation Immunosuppression kidney kidney transplant recipient kidney transplant recipients Kidney transplantation mRNA mRNA vaccine Nephrology neutralization neutralization titer neutralization titers Neutralizing Neutralizing antibodies neutralizing antibody Observational cohort study organ organ transplantation patients Practice reduced SARS-CoV-2 SARS-CoV-2 vaccine sera Seroconversion Seropositivity significantly significantly lower solid organ solid organ transplantation the SARS-CoV-2 Vaccine vaccine dose variant variants of concern wild-type
[DOI] 10.1111/ajt.17054 PMC 바로가기 [Article Type] Observational Study

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

SARS-CoV-2 mRNA 백신 접종 후 6개월 후 체액성 면역 반응의 현저한 감소 특성: 체계적인 검토

Review

Published on 2022-07-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-Spike IgG antibody Antibody Response Antibody titer Antibody titers appearance article binding domain BNT161b2 BNT162b2 booster Breakthrough infection breakthrough infections calculated characterization Comorbidities coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA Vaccination determine Effect Efficacy Evidence exhibited Factor finding highlight humoral humoral immune response Humoral immunity Humoral response IgG Immunoglobulin Immunoglobulin G independent independent of Kinetics Longitudinal data Messenger RNA Moderna mRNA mRNA 1273 mRNA BNT162b2 mRNA vaccination mRNA-1273 Participants peak levels Pfizer-BioNTech postvaccination presence of comorbidities reached reported respiratory second dose serostatus Serum level serum levels severe acute respiratory syndrome Coronavirus Sex systematic review Vaccination strategy Vaccine Vaccines variant waning immunity was performed
[DOI] 10.1002/jmv.27688 PMC 바로가기 [Article Type] Review

Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon

브라질 아마존에서 SARS-CoV-2 Mu 변종(B.1.621) 지역사회 전파에 대한 능동적 감시 및 조기 탐지

Article

Published on 2022-07-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] Active surveillance All participants Amino acid amino acid substitution Antigen assist Asymptomatic B.1.621 blood sample Blood samples Brazilian Amazon Chain Reaction circulating city collected Community community transmission Contact tracing country COVID-19 patient Diagnosis diagnostic test ELISA testing Emergency epidemiological data followed by genomic genomic sequencing Genomic surveillance highlight household contacts identify IgA IgG IgG levels IgM antibody IgM antibody levels individual infected individual information mild symptoms Mu variant nasopharyngeal swabs one patient ORF1a ORF7a outpatients Participants polymerase chain reaction Porto prospective cohort Rapid diagnostic test reference sequence Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequenced specimen Surveillance Swab tested Travel variant virus viruses
[DOI] 10.1002/jmv.27686 PMC 바로가기 [Article Type] Article